Samsung Bioepis is reportedly undertaking shorter clinical trials in order to gain faster biosimilar approvals as the company seeks to compete with rival developers and to realize its first annual profits.
Samsung Bioepis is reportedly undertaking shorter clinical trials in order to gain faster biosimilar approvals as the company seeks to compete with rival developers and to realize its first annual profits.
According to The Investor, Samsung has shortened the duration of its clinical trials to 1 year in an effort to report its data more quickly. Additionally, the Korean biosimilar developer has sent its staff around the globe to the locations of its clinical trials—rather than relying on contract research organizations—in order to better control its timetables and speed approvals.
These efforts, says The Investor, are designed to help the 5-year-old Samsung Bioepis to both gain the competitive advantage of a robust pipeline and to turn a profit after posting annual losses throughout its short history. The company is, however, unlikely to become profitable until its drugs find greater uptake in the US and European markets.
Samsung Bioepis, whose infliximab (Renflexis) was approved by the FDA in April of this year, currently has 4 biosimilar candidates in phase 3 development for the US marketplace. Those drugs are etanercept (SB4 Benepali, referenced on Enbrel), adalimumab (SB5 Imraldi, referenced on Humira), trastuzumab (SB3, referenced on Herceptin), and bevacizumab (SB8, referenced on Avastin). By contrast, the company’s chief rival, fellow Korean biosimilar developer Celltrion, has only 1 biosimilar candidate in phase 3 development for the US market: trastuzumab (CT-P6 Herzuma, referenced on Herceptin).
Yet Samsung Bioepis faces other time-consuming roadblocks to its US sales objectives; in May, Janssen Biotech filed a district court lawsuit to prevent the sale of Samsung Bioepis’ FDA-approved infliximab biosimilar in the United States.
However, that lawsuit hinges on Samsung Bioepis’ purported failure to complete the patent information exchange process as laid out in the Biologics Price Competition and Innovation Act (BPCIA), as well as on the company’s early notice of commercial marketing. The suit finds itself on questionable footing after the Supreme Court’s June ruling in Sandoz v Amgen, which determined that there exists no federal remedy for a failure to engage in the “patent dance,” and that biosimilar makers can provide notice of commercial marketing either before or after FDA approval of a biosimilar product.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).
Biosimilars Business Roundup For August 2023—Podcast Edition
September 5th 2023On this episode, we’re giving an overview of some of the biggest stories in the business space regarding biosimilars, like the approval of the first neurology biosimilar, growth projections from company quarterly expense reports, and some analyses about the health of the market.
AMCP Nexus: Panelists Share Current Scope of Biosimilar Industry
October 26th 2023Panelists at the Academy of Managed Care Pharmacy (AMCP) Nexus meeting chronicled the current state of the US biosimilar market, including current policies impacting the market, recent regulatory decisions, and the developing arguments around requirements for clinical efficacy studies.
Report: Conflicting Guidelines, Rebate Walls Are Major Factors Determining Biosimilar Uptake
October 24th 2023Samsung Bioepis’ most recent biosimilar market report identified inconsistent medical guidelines, challenges with access and rebates, and acute vs chronic treatment duration as major factors influencing biosimilar uptake in the United States.